The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | NUTRIVENTION-5: a dietary intervention for NDMM with standard induction chemotherapy
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, gives an update on the NUTRIVENTION-5 study (NCT07226609), which will investigate the impact of a dietary intervention on treatment response and/or quality of life for people with newly diagnosed multiple myeloma (NDMM) receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). If you’re interested in getting in touch, please contact: shahnutrivention@mskcc.org. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
